Effect of whole and fractionated intravenous immunoglobulin on complement in vitro

Molecular Immunology

Volumn 34, Issue 10, 1997, Pages 719-729

  Mollnes, Tom E ^a   Andreassen, Iren H ^b   Høgåsen, Kolbjørn ^b   Hack, C Erik ^c   Harboe, Morten ^b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Classical pathway; Clq; Complement; Intravenous immunoglobulins; IVIG

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DOSE RESPONSE; FRACTIONATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN STRUCTURE; IMMUNOMODULATION; INFLAMMATION; PRIORITY JOURNAL;

ANIMALS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ERYTHROCYTES; HEATING; HEMOLYSIS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; SHEEP;

EID: 0031435056     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(97)00091-6     Document Type: Article

References (40)

1. Atkinson J. P., Fisher R. I., Reinhardt R. and Frank M. M. (1978) Reduced concentrations of the first component of complement in hypogammaglobulinemia: correction by infusion of gamma-globulin. Clinical Immunology and Immunopathology 9, 350-355.
2. Basta M. (1996) Modulation of complement-mediated immune damage by intravenous immune globulin. Clinical and Experimental Immunology 104, 21-25.
3. Basta M. and Dalakas M. C. (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. Journal of Clinical Investigation 94, 1729-1735.
4. Basta M., Fries L. F. and Frank M. M. (1991a) High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77, 376-380.
5. Basta M., Fries L. F. and Frank M. M. (1991b) High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway. Blood 78, 700-702.
6. Basta M., Kirshbom P., Frank M. M. and Fries L. F. (1989) Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. Journal of Clinical Investigation 84, 1974-1981.
7. 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clinical Immunology and Immunopathology 34, 227-236.
8. Bing D. H. (1983) The interaction of immune serum globulin and immune globulin intravenous with complement. Molecular Immunology 20, 893-900.
9. Bonara P., Gridelli B., Galli A., Gatti S., Tedeschi S., Reggiani P., Mocellin M. C., Prato P., Langer M. and Galmarini D. (1996) In vitro and in vivo effects of polyclonal human intravenous immunoglobulins in discordant xeno-transplantation. Transplantation Proceedings 28, 778-783.
10. Brekke O. H., Michaelsen T. E. and Sandlie I. (1995) The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunology Today 16, 85-90.
11. Fure H., Nielsen E. W., Hack C. E., Mollnes T. E. (in press) A neoepitope based enzyme immunoassay for quantification of C1-inhibitor in complex C1r and C1s. Scandinavian Journal of Immunology.
12. Garred P., Mollnes T. E. and Lea T. (1988) Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scandinavian Journal of Immunology 27, 329-335.
13. Garred P., Mollnes T. E., Lea T. and Fischer E. (1988) Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Scandinavian Journal of Immunology 27, 319-327.
14. Kohler P. F., Muller Eberhard H. J. (1969) Complement-immunoglobulin relation: deficiency of C1q associated with impared immunoglobulin G synthesis. Science 163, 474-475.
15. Kojima T., Hayashi S., Yokoyama I. and Takagi H. (1996) Role of Fc fragments in inhibition of xenogenic hyperacute rejection by intravenous immunoglobulin. Transplantation 62, 559-562.
16. Lutz H. U., Stammler P., Jelezarova E., Nater M. and Spath P. J. (1996) High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3b(n)-IgG complexes. Blood 88, 184-193.
17. Magee J. C., Collins B. H., Harland R. C., Lindman B. J., Bollinger R. R., Frank M. M. and Platt J. L. (1995) Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. Journal of Clinical Investigation 96, 2404-2412.
18. Miletic V. D. and Frank M. M. (1995) Complement immunoglobulin interactions. Current Opinion in Immunology 7, 41-47.
19. Miletic V. D., Hester C. G. and Frank M. M. (1996) Regulation of complement activation by immunoglobulin. 1. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. Journal of Immunology 156, 749-757.
20. Mollnes T. E., Hogasen K., Hoaas B. F., Michaelsen T. E., Garred P. and Harboe M. (1995) Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scandinavian Journal of Immunology 41, 449-456.
21. Mollnes T. E., Lea T., Froland S. S. and Harboe M. (1985) Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scandinavian Journal of Immunology 22, 197-202.
22. Mollnes T. E., Lea T., Harboe M. and Tschopp J. (1985) Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scandinavian Journal of Immunology 22, 183-195.
23. Mollnes T. E., Redl H., Hogasen K., Bengtsson A., Garred P., Speilberg L., Lea T., Oppermann M., Gotze O. and Schlag G. (1993) Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clinical and Experimental Immunology 91, 295-300.
24. Mouthon L., Kaveri S. V., Spalter S. H., Lacroix Desmazes S., Lefranc C., Desai R. and Kazatchkine M. D. (1996) Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clinical and Experimental Immunology 104, 3-9.
25. Nielsen H. (1994) Immunoglobulin preparations for intravenous administration - a review of their biologic activities and comparison of various preparation methods. Allergy 49, 69-73.
26. Nomura S., Miyazaki Y., Miyake T., Yamaguchi K., Kido H., Kawakatsu T., Fukuroi T., Kagawa H., Suzuki M., Yanabu M. and Kokawa T. (1993) IgG inhibits the increase of platelet-associated C(3) stimulated by anti-platelet antibodies. Clinical and Experimental Immunology 93, 452-455.
27. Nuijens J. H., Huijbregts C. C., Eerenberg Belmer A. J., Abbink J. J., Strack van Schijndel R. J., Felt Bersma R. J., Thijs L. G. and Hack C. E. (1988) Quantification of plasma factor XIIa-Cl-inhibitor and kallikrein-Cl-inhibitor complexes in sepsis. Blood 72, 1841-1848.
28. Qi M. and Schifferli J. A. (1995) Inhibition of complement activation by intravenous immunoglobulins. Arthritis and Rheumatism 38, 146.
29. Rasmussen J. M., Brandslund I. and Svehag S. E. (1984) In vitro investigations of human immunoglobulin preparations: Fc-receptor reactivity and complement consumption. APMIS 92, 335-340.
30. Romer J., Spath P. J., Skvaril F. and Nydegger U. E. (1982) Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to Staphylococcus protein A. Vox Sanguinis 42, 74-80.
31. Roux K. H. and Tankersley D. L. (1990) A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. Journal of Immunology 144, 1387-1395.
32. Schumaker V. N., Calcott M. A., Spiegelberg H. L., Muller-Eberhard H. J. (1976) Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 15, 5175-5181.
33. Schumaker V. N., Hanson D. C., Kilchherr E., Phillips M. L. and Poon P. H. (1986) A molecular mechanism for the activation of the first component of complement by immune complexes. Molecular Immunology 23, 557-565.
34. Tankersley D. L. (1994) Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunolological Reviews 139, 159-172.
35. Tschopp J., Villiger W., Fuchs H., Kilchherr E. and Engel J. (1980) Assembly of subcomponents C1r and C1s of first component of complement: electron microscopic and ultracentrifugal studies. Proceedings of the National Academy of Sciences U.S.A. 77, 7014-7018.
36. Vassilev T. L., Bineva I. L., Dietrich G., Kaveri S. V. and Kazatchkine M. D. (1995) Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. Journal of Autoimmunity 8, 405-413.
37. White K. D., Frank M. B., Foundling S. and Waxman F. J. (1996) Effect of immunoglobulin variable region structure on C3b and C4b deposition. Molecular Immunology 33, 759-768.
38. Wolbink G. J., Bollen J., Baars J. W., Tenberge R. J. M., Swaak A. J. G., Paardekooper J. and Hack C. E. (1993) Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. Journal of Immunological Methods 163, 67-76.
39. Wright J. K., Tschopp J., Jalon J. C. and Engel J. (1980) Dimeric, trimeric and tetrameric complexes of immunoglobulin G fix complement. Biochemistry Journal 187, 775-780.
40. Zang X. X., Sun Y., Shen F., Wang D., Zhou L. and Wang J., Kung E. (1995) Molecular structure alteration of IgG increased anticomplementary activity of intravenous immunoglobulin. Acta Pharmacologica Sinica 16, 415-419.